Monday, October 5, 2026

Business

9 articles

Boycott Apps Surge in Denmark Over Trump's Greenland Dispute

Boycott Apps Surge in Denmark Over Trump's Greenland Dispute

A mobile app that helps shoppers avoid American products has seen a surge in downloads in Denmark, fueled by tensions over Trump's remarks about Greenland. This trend highlights growing consumer nationalism and could impact global trade relations.

ViaNews Editorial Team (Markets)•
Made O'Meter App Sparks European Boycott Movement Over Greenland

Made O'Meter App Sparks European Boycott Movement Over Greenland

Mobile apps helping shoppers avoid American products see surge in Danish downloads, reflecting growing tensions over Trump's remarks on Greenland. This trend highlights shifting consumer preferences and potential impacts on global trade.

ViaNews Editorial Team (Markets)•
Sanmina Eyes $16B Revenue by 2027 on AI Data Center Growth

Sanmina Eyes $16B Revenue by 2027 on AI Data Center Growth

Sanmina Corporation reported robust Q1 2026 earnings, with management expressing satisfaction over the results. However, analysts remain divided, with some bullish on AI-driven growth while others warn of potential risks.

ViaNews Editorial Team (Markets)•
Tesla Reports Second Consecutive Sales Decline as BYD Overtakes in EV Market

Tesla Reports Second Consecutive Sales Decline as BYD Overtakes in EV Market

Tesla delivered 418,227 vehicles in Q4 2025, marking its second consecutive annual sales decline and ceding the top spot to BYD. Analysts see potential in Tesla's energy storage and autonomous driving initiatives, but warn of intensifying competition and weakening demand.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com